NewAmsterdam Pharma Company N.V. (NAMS)
NewAmsterdam Pharma Company N.V. operates in the Biotechnology industry of the Healthcare sector, headquartered in Naarden, NH, NL. The stock last traded at $22.58, down 0.70% on the session, giving a market capitalisation of $2.64B. On trailing twelve-month figures it carries a trailing P/E of -10.36, a net margin of -3644.2%. Its beta of 0.09 implies it has historically moved less than the broad market.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NewAmsterdam Pharma Company N.V. is most often compared with the following Healthcare names: